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ABSTRACT 
Aims. The discovery of methionine metabolism enzymes in the cell nucleus, together 
with their association with key nuclear processes, suggested a putative relationship 
between alterations in their subcellular distribution and disease. Results. Using the rat 
model of D-galactosamine intoxication severe changes in hepatic steady-state mRNA 
levels were found; the largest decreases corresponded to enzymes exhibiting the highest 
expression in normal tissue. Cytoplasmic protein levels, activities and metabolite 
concentrations suffered more moderate changes following a similar trend. Interestingly, 
galactosamine-treatment induced hepatic nuclear accumulation of MATα1 and S-
adenosylhomocysteine hydrolase tetramers, their active assemblies. In fact, 
galactosamine-treated livers showed enhanced nuclear methionine adenosyltransferase 
activity. Acetaminophen intoxication mimicked most galactosamine effects on hepatic 
MATα1, including accumulation of nuclear tetramers. H35 cells overexpressing tagged-
MATα1 reproduced the subcellular distribution observed in liver, and the changes 
induced by galactosamine and acetaminophen that were also observed upon glutathione 
depletion by buthionine sulfoximine. The H35 nuclear accumulation of tagged-MATα1 
induced by these agents correlated with decreased GSH/GSSG ratios and was prevented 
by N-acetylcysteine and glutathione ethyl ester. However, the changes in epigenetic 
modifications associated with tagged-MATα1 nuclear accumulation were only 
prevented by N-acetylcysteine in galactosamine-treated cells. Innovation. Cytoplasmic 
and nuclear changes in proteins regulating the methylation index follow opposite trends 
in acute liver injury, their nuclear accumulation showing potential as disease marker. 
Conclusion. Altogether these results demonstrate galactosamine- and acetaminophen-
induced nuclear accumulation of methionine metabolism enzymes as active oligomers 
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and unveil the implication of redox-dependent mechanisms in the control of MATα1 
subcellular distribution.  
 
Keywords: Methionine adenosyltransferase, methylation index, epigenetic 
modifications, redox stress. 
Delgado et al. 
 4 
INTRODUCTION 
 Methionine is an essential amino acid that is mainly metabolized in the liver for 
protein and S-adenosylmethionine (AdoMet or SAM) synthesis. Reductions in AdoMet 
levels occur in a multitude of pathologies that include from cancer to acute liver failure 
(31, 37, 45). Three methyltransferases, among them glycine N-methyltransferase 
(GNMT), account for most of hepatic AdoMet consumption (32, 39). Methylations 
generate S-adenosylhomocysteine (AdoHcy), a potent inhibitor of many 
methyltransferases (9), the ratio AdoMet/AdoHcy (methylation index) determining the 
flow through these reactions (45). Methionine adenosyltransferases (MATs) are the only 
known enzymes that catalyze AdoMet synthesis using methionine and ATP in the first, 
and rate-limiting, reaction of the methionine cycle (45). AdoMet is used primarily for 
transmethylation reactions, but also by SAM radical proteins and after decarboxylation 
for polyamine biosynthesis (37, 45). S-adenosylhomocysteine hydrolase (SAHH) 
eliminates AdoHcy in a reversible reaction that favors its synthesis, unless 
homocysteine (Hcy) and adenosine are efficiently removed. Hcy can be remethylated to 
methionine by methionine synthase (MTR) or betaine homocysteine methyltransferase 
(BHMT), transported into the blood or enter the trans-sulfuration pathway (46). This 
last pathway connects methionine metabolism with cysteine and glutathione production, 
and hence with redox control. 
 Regulation of the methionine cycle is complicated by the existence of several 
isoenzymes (MAT I, II and III), the action exerted by several metabolites (AdoMet, 
AdoHcy) and the existence of homo- (i.e. MAT I and III, BHMT) and hetero-oligomers 
(MAT II) (45, 46). Different regulatory mechanisms contribute to determine the final 
outcome, involving: i) hormones, acting primarily at the transcriptional level (18); ii) 
metabolites that activate or inhibit several steps (e.g. AdoMet); iii) related metabolites 
Delgado et al. 
 5 
that modulate expression (e.g. methylthioadenosine), activity and oligomerization (e.g. 
glutathione and NADP+)(12, 20, 44). 
 Many studies have been focused in analyzing the changes in expression, protein 
levels, and activity of MAT isoenzymes and their relationship with disease. Among 
them, rat models of galactosamine and CCl4 intoxication in combination with biopsies 
of human cirrhotic livers showed decreased MAT activity and reductions in the MAT I 
(tetramer of α1) to MAT III (dimer of α1) activity ratio (7, 11). Additional studies 
demonstrated an expression switch from MAT1A (encoding α1 subunits) to MAT2A 
(encoding α2 subunits of MAT II) in hepatoma, resembling the fetal expression pattern 
(17). These changes decreased AdoMet concentrations, given the differences in Vmax 
and methionine affinity of the isoenzymes (33, 45). The importance of AdoMet levels in 
liver disease was further demonstrated when mice exhibiting low (MAT1A -/-) and high 
(GNMT -/-) hepatic AdoMet levels were produced (30, 35). These mice developed HCC 
spontaneously, highlighting the necessity of a strict control of AdoMet homeostasis for 
normal liver function.  
 Recently, nuclear localization of some methionine cycle enzymes was reported. 
Nuclear MATα1 accumulation correlated with increased histone 3 K27 trimethylation 
(me3K27H3), an epigenetic modification related to gene repression (50). Nuclear 
MATα2 has been found acting as a MafK corepressor and interacting with histone 3 K9 
and K4 dimethylating enzymes (26), and nuclear SAHH was related to efficient RNA 
cap methylation (49). However, the mechanisms regulating subcellular distribution of 
these proteins and its relationship with disease remain unknown. For this purpose, we 
have used models of acute liver injury as suitable experimental settings and found 
nuclear accumulation of methionine metabolism enzymes, together with the implication 
of a redox-dependent mechanism in the process. Altogether the results presented sustain 
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the novel paradigm of gene expression regulation through the nuclear shuttling of 
enzymes controlling the methylation index. 
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RESULTS 
 The rat model of D-galactosamine intoxication has been previously used to 
analyze changes in AdoMet production in hepatopathy, by measuring cytosolic MAT 
activity and AdoMet levels (7, 58). We reproduced this model in search of a putative 
link among disease and nucleocytoplasmic distribution of methionine cycle enzymes. 
No changes in liver weight, but striking differences in histology, between animals 
included in control and galactosamine groups were found (Supplementary Fig. S1). 
Control livers had normal appearance in hematoxylin/eosin staining, whereas 
galactosamine-treated animals showed intrasinusal lymphocytes, signs of steatosis and 
small focuses of necrosis. Galactosamine also induced a dramatic increase in serum 
transaminases, together with a significant reduction in hepatic AdoMet levels and total 
MAT activity (Supplementary Tables S1, S2). Analytical gel filtration chromatography 
(AGFC) showed a larger decline in MAT I than in MAT III activity, thus changing the 
MAT III/I ratio (Supplementary Fig. S2A, C, Table S1). Hence, the treatment was 
effective, livers showing the expected signs of hepatopathy and the previously reported 
changes.  
 The model was further characterized by real-time PCR analysis of steady-state 
mRNA levels of the methionine cycle enzymes, using the 18S gene as reference (Fig. 
1A). Severe reductions (70-80%) in MAT1A, BHMT and GNMT transcripts were 
detected upon galactosamine treatment, whereas mRNA levels for the rest of the 
enzymes increased; the largest changes corresponded to MAT2A (500%) and MAT2B 
(250%) transcripts, while more moderate elevations (~150-200%) were detected for 
MTR and SAHH. Therefore, a MAT1A to MAT2A expression switch was clearly visible 
after 48 hours of treatment, the relative expression levels of both transcripts becoming 
similar (Fig. 1B). Additionally, galactosamine induced the expression of both γ-
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glutamylcysteine synthetase (GCL) subunits, modifier (GCLm) and ligase (GCLl), by 
350% (Fig. 1A).  
 The consequences of these expression changes on protein levels were then 
analyzed in liver cytosols using α-tubulin as reference (Fig. 2A). Reductions (40-45%) 
in MATα1 and BHMT levels were detected upon galactosamine treatment, whereas 
SAHH levels increased (190%) and those of GNMT remained unaffected (Fig. 2B). 
Protein changes were more moderate than in transcript levels, thus putative alterations 
in mRNA and protein half-lives were explored. For this purpose, we first assessed 
whether the hepatic effects induced by galactosamine could be reproduced in H35 cells. 
Cytosolic BHMT protein levels decreased ∼30%, whereas those of SAHH increased 
∼100% in galactosamine-treated cells, following the same trend observed in liver 
cytosols (Fig. 2C-D). Neither MATα1 nor GNMT were detected in control H35 cells as 
previously reported, although a faint GNMT band could be observed in cytosols of 
treated cells (Fig. 2E). Transient transfection with pHA-MAT allowed analysis of HA-
MATα1, a tagged-MATα1 that exhibited MAT activity and the expected size and 
preserved the oligomerization features of MATα1 (Supplementary Fig. S3-5). These 
transfected cells exhibited a 65% decrease in cytosolic HA-MATα1 levels after 
galactosamine treatment (Fig. 2F). Altogether, H35 cells reproduced liver behavior, 
allowing their use to evaluate putative changes in half-life. MAT2B, GCLm and GCLl 
transcripts increased their half-lives by galactosamine treatment, whereas those of 
SAHH and BHMT decreased or showed a trend towards reduction, respectively 
(Supplementary Table S3). In contrast, cytosolic BHMT and SAHH protein half-lives 
increased 200% by galactosamine treatment (Supplementary Table S3). 
 Next, changes in representative enzyme activities were measured in liver 
cytosols (Supplementary Table S1). Total MAT activity (MAT I + MAT II + MAT III) 
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decreased 50% in the galactosamine group, but no changes were detected using 60 µM 
methionine and only a tendency towards increase was observed by DMSO activation of 
MAT III. These activity changes seemed compensated by the reduction in MATα1 
protein levels (Fig. 2A). The treated group also showed a 25% reduction in BHMT 
activity, a modest change compared to alterations in mRNA and protein levels. 
Evaluation of hepatic metabolite changes by UPLC-MS showed the already mentioned 
reduction in AdoMet levels in the galactosamine group, together with enhanced levels 
of Hcy, methionine and, particularly, in GSSG (Supplementary Table S2). These 
changes caused a 30% decrease in the hepatic methylation index (AdoMet/AdoHcy) and 
the GSH/GSSG ratio.  
 Putative changes in the cytosolic association state of hepatic methionine cycle 
enzymes were evaluated by AGFC, confirming the previously described increase in 
MAT III activity in the galactosamine group (7), and hence a rise in the calculated 
dimer/tetramer activity ratio (Supplementary Fig. S2A, C and Supplementary Table S1). 
Additionally, dot-blot evaluation of MATα1 protein in the column fractions showed a 
strong reduction in the signal of the galactosamine group, where only MAT III 
oligomers were detected (Supplementary Fig. S2B, D). Calculated MAT III/I protein 
ratios were 11.64 ± 3.96 and 24.66 ± 5.38 (p=0.001) for control and treated groups, 
respectively. In contrast, cytosolic SAHH, GNMT and BHMT exhibited no alteration in 
their association state (Supplementary Fig. S6).  
 Putative changes on MATα1 subcellular localization induced by galactosamine 
were then analyzed using initially transiently transfected H35 cells (Fig. 3). Only 15% 
of the control cells showed nuclear accumulation (N/C>1.2) by indirect 
immunofluorescence, a percentage that increased to ∼60% after galactosamine 
treatment. In vivo confocal microscopy also demonstrated nuclear accumulation in 
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∼30% and ∼90% of the control and galactosamine-treated cells, respectively, whereas 
controls expressing EGFP showed no alteration in subcellular distribution. MATα1 
nuclear accumulation was confirmed by subcellular fractionation showing a 60% 
increase in HA-MATα1, together with a ∼170% increase in nuclear SAHH in the 
treated group (Fig. 4A, B). Subcellular fractions of control and galactosamine-treated 
rat livers confirmed the increased nuclear MATα1 (200%) and SAHH (240%) levels, 
together with an elevated GNMT content (Fig. 4C, D). Immunohistochemistry further 
reinforced these results showing MATα1 cytoplasmic localization in control livers and 
nuclear staining in galactosamine-treated tissues (Fig. 5). 
 Methionine cycle enzymes are oligomers in the cytoplasm, but the nuclear 
association state has been only determined for MATα1 (50). Therefore, we used AGFC 
to analyze possible changes in this parameter, and detected that the increased content of 
GNMT and SAHH in nuclear fractions of galactosamine-treated livers did not involve 
alterations in their elution pattern (Fig. 6A, B). Calculated elution volumes, 11.76 ml for 
GNMT and 11.13 ml for SAHH, corresponded to compact homo-tetramers of 133 and 
171 kDa, respectively. In contrast, accumulation of nuclear MATα1 in treated livers 
occurred as tetramers with a parallel reduction in the monomer content (Fig. 6C), and 
the corresponding decrease in the calculated monomer/tetramer ratios (7.32 ± 2.44 vs. 
3.07 ± 1.11; p=0.024) (Fig. 6D). MAT catalysis requires oligomerization, hence the rise 
in nuclear MAT I content suggested an increase in activity that was in fact detected. 
Galactosamine treatment resulted in a 250% increase of nuclear MAT activity as 
compared to the controls (45.67 ± 15.19 vs. 15.82 ± 8.86 pmol/min/mg, p=0.003). 
 Next, several redox-modulating agents and transiently transfected H35 cells 
were used to get insight into the mechanisms governing MATα1 subcellular 
distribution. Reductions in HA-MATα1 cytoplasmic content were found, concomitantly 
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with nuclear accumulation, upon treatments with galactosamine (∼60%; Fig, 7A, C) and 
BSO (∼30%; Fig. 7B, D), an inhibitor of glutathione synthesis. N-acetylcysteine (NAC) 
and AdoMet prevented galactosamine effects on cytosolic protein levels, whereas 
nuclear changes were only prevented by NAC (Fig. 7A, C). BSO-induced alterations in 
HA-MATα1 levels were prevented by EGSH in both subcellular fractions, but not by 
AdoMet (Fig. 7B, D). Analysis of the glutathione levels and the GSH/GSSG ratio 
showed that only agents that prevented large alterations in these parameters (NAC and 
EGSH) were able to maintain the control nucleocytoplasmic distribution 
(Supplementary Fig. S7). No signs of apoptosis were detected in extracts of the 
different treatments, according to the lack of caspase-3 activation, but moderate changes 
in LDH activity in the culture media of galactosamine-treated cells were observed 
(Supplementary Fig. S8, S9A). The effects described were confirmed in vivo by 
confocal microscopy using pMAT-EGFP transfected H35 cells and the same agents 
(Supplementary Fig. S10A). Quantification of the N/C signal ratio indicated 250% 
increases upon galactosamine or BSO treatments, whereas NAC and EGSH partially 
prevented the effects on subcellular localization (Supplementary Fig. S10A-C).  
 An enhanced nuclear capacity to produce AdoMet may be required to support 
key epigenetic modifications involving methylation, some of which were measured. No 
significant changes were observed in DNA methylation levels of both rat livers and 
pHA-MAT-transfected H35 cells, although a trend towards reduction was detected in 
the galactosamine-treated samples (Fig. 8A, B). In contrast, a 300% increase in 
me3K27H3 levels was detected in pHA-MAT-transfected cells receiving galactosamine, 
and NAC prevented this increase (Fig. 8C, D). Therefore, nuclear accumulation of HA-
MATα1 correlated positively with me3K27H3 upon galactosamine treatment.  
Delgado et al. 
 12 
 Finally, the effects of acetaminophen (APAP) intoxication on MATα1 
nucleocytoplasmic distribution were also examined, given its known effects on 
methionine metabolism and GSH levels. An acute dose of the drug induced dramatic 
increases in rat serum transaminase levels (Supplementary Table S4), together with 
focal necrosis that was visible upon eosin/hematoxylin staining of liver sections 
(Supplementary Fig. S11). APAP induced significant decreases in hepatic levels of 
methionine, AdoMet, GSSG and more severe on AdoHcy and GSH that resulted in an 
increased methylation index, together with a 25% decrease in the GSH/GSSG ratio 
(Supplementary Table S4). APAP-treated livers showed a 200% elevation of the nuclear 
MATα1 content, without significant changes in cytoplasmic levels as judged by western 
blot (Supplementary Fig. S12). In contrast, a 20% decrease in cytosolic MAT activity 
was detected in the presence of 60 µM or 5 mM methionine, and no significant changes 
were measured by DMSO activation (Supplementary Table S4). These data suggested 
an effect of APAP directed towards MAT I activity that was further analyzed by AGFC. 
Opposite behaviors for dimer/tetramer activity and protein ratios were detected in the 
cytosol. Thus, while the MAT III/I activity ratio increased 200%, reflecting a decrease 
in MAT I activity, the protein ratio was reduced by the increased tetramer content 
(Supplementary Fig. S12C, D). In parallel, the nuclear monomer/tetramer ratio 
decreased due to a significant increase in MAT I levels, without modification of the 
total nuclear MAT activity (Supplementary Fig. S12E-G). This lack of changes in 
nuclear MAT activity presented with a trend towards reduction in hepatic global DNA 
methylation (Supplementary Fig. S13A). Nuclear accumulation of MATα1-EGFP was 
also shown by in vivo confocal microscopy in H35-transfected cells upon APAP 
treatment, an effect that was partially prevented by NAC (Supplementary Fig. S10D, E). 
APAP, NAC or their combination induced no significant changes in DNA methylation 
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as compared to cells receiving the vehicle (Supplementary Fig. S13B). However, APAP 
increased me3K27H3 methylation (200%), an effect that was not prevented by NAC, 
despite the normalization of glutathione levels and the GSH/GSSG ratio 
(Supplementary Fig. S7C). Extracts from APAP-treated cells showed activated caspase-
3 (19-17 kDa) and increased LDH activity (∼170%) in the culture media, suggestive of 
apoptosis (Supplementary Fig. S8B, S14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delgado et al. 
 14 
DISCUSSION 
 Many liver diseases associated with impairment of methionine metabolism 
proceed with changes in the MAT isoenzymes expressed (MAT1A to MAT2A switch)(7, 
12, 14, 31, 33, 56, 61). By this expression switch the cell changes from high to low Vmax 
MAT isoenzymes with the corresponding reductions in MAT activity, AdoMet levels 
and the methylation index. Additionally, liver injury concurs with decreases in GSH 
content and/or increases in GSSG, NO concentrations and ROS levels that are known to 
inhibit cytosolic MAT I/III and, in some cases, change the dimer/tetramer ratio (28, 34, 
38, 40, 42, 44, 52, 56). Galactosamine and APAP differ notably in their mechanisms of 
action (5, 27), but acute doses of both agents induce liver injury with the mentioned 
alterations in hepatic metabolism (7, 42, 56, 58). Our results confirm these previous 
observations upon galactosamine treatment, together with a modest increase in MAT2B 
and MTR mRNA levels and a strong decrease in GNMT and BHMT transcripts 
(Supplementary Fig. S15). These expression changes resemble alterations reported in 
APAP intoxication, except for SAHH and GNMT levels that were transiently elevated in 
this model (56). Protein levels follow the same trend than mRNA in galactosamine 
intoxication, although more modest alterations are detected, due in some cases to 
opposite changes in their half-lives. Galactosamine also induces expression of both 
GCL subunits, whereas APAP and other hepatotoxicants only increase GCLl expression 
(22, 56). Putative mechanisms by which expression changes take place may involve the 
presence of antioxidant response elements (AREs) in the corresponding promoters (25), 
the uridine depletion induced by galactosamine (27), and stabilization/destabilization of 
the corresponding transcripts through binding to HuR or AUF1, respectively, as has 
been demonstrated for MAT2A and MAT1A mRNAs during liver carcinogenesis (36, 
59).  
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 All these alterations result in reductions of hepatic AdoMet levels in 
galactosamine and APAP intoxications, as previously described (7, 42, 43, 56, 58). 
However, AdoHcy and methionine concentrations follow opposite trends in both 
models, probably due to the combination of divergent changes in SAHH, GNMT, 
BHMT and MTR expression and protein levels, as well as in the flux through the trans-
sulfuration pathway (56). Galactosamine effects in methionine and AdoMet are also 
supported by the previously reported decreases in ATP and sarcosine levels found in 
isolated hepatocytes (43). Additionally, decreased AdoMet levels could contribute to 
this picture by avoiding activation of trans-sulfuration (37, 46), increasing BHMT 
expression (46)(not observed with galactosamine), contributing to methionine and folate 
recycling by enhancing MTHFR activity and increasing MTR expression (57), and 
modulating HuR nucleocytoplasmic distribution, and hence contributing to increase 
MAT2A mRNA levels (36). Furthermore, an increased MTFHR activity leads to higher 
5-methyltetrahydrofolate levels that inhibit GNMT (32), whereas decreased BHMT 
levels would result in lower betaine consumption, increasing protection against protein 
conformational changes (10). Both drugs lead also to a compensatory increase of 
GCL expression that should render enhanced total glutathione levels. 
Nevertheless, such an increase is only observed for galactosamine, probably due to 
the different detoxification mechanisms used by both drugs. Such mechanisms 
may require a larger amount of glutathione for APAP metabolization than for 
galactosamine-derived ROS removal. However, the net results are reduced 
GSH/GSSG ratios that likely reflect the GSH consumption needed for NAPQI 
generation and the GSSG production due to galactosamine-ROS elimination, as well as 
the galactosamine inhibition of glutathione recycling enzymes (5, 29, 40, 48). 
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These global effects of galactosamine and APAP on metabolite concentrations 
reflect mainly cytosolic changes, but may not mirror those in other subcellular 
compartments with different functions and needs. Classically, methionine metabolism 
was considered a cytoplasmic pathway and metabolites, such as AdoMet, expected to 
move to compartments where methylation reactions were held. This hypothesis was 
supported by the cytoplasmic localization of the enzymes and the existence of AdoMet 
transporters (23, 33, 45). However, recent reports described nuclear localization of 
SAHH, GNMT, MATα1, MATα2 and MATβ that was related to in situ production of 
AdoMet and AdoHcy elimination (26, 49, 50, 60, 62). Hence, the paradigm has changed 
to propose that enzymes are transported to those locations where metabolite synthesis is 
needed (16). Nevertheless, the mechanisms involved in the control of their subcellular 
distribution and their relationship to disease remain unknown. Here, we show that 
APAP and galactosamine intoxications induce nuclear accumulation of MATα1 and 
increased MAT I levels that correlate with reduction (galactosamine) or no change 
(APAP) of the cytosolic protein levels, together with opposite consequences on the 
MAT III/I protein ratio. Alterations at the protein level only match the total MAT 
activity of both compartments in galactosamine intoxication, whereas higher MAT I 
levels in APAP treatment correlate with reduction (cytoplasm) or no effect (nucleus) in 
this parameter. These differential effects on cytosolic and nuclear MAT activities may 
rely on the induction of reversible (GSSG, NO and ROS) and/or irreversible (NAPQI) 
modifications of the protein (4, 5, 42, 53), in the association capacity of the nuclear 
monomer pool into MAT I and additionally on the moderate APAP dose used.  
Epigenetic remodeling is required for the induction/repression of genes involved 
in defense mechanisms, apoptosis or necrosis during progression of liver damage. The 
nuclear increase in MAT I induced by galactosamine and APAP may respond to higher 
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AdoMet needs in this compartment, as reflected by the rise in me3K27H3 levels in 
H35-treated cells, and the subtle DNA hypomethylation in the galactosamine model. 
These results confirm previous data associating MATα1 overexpression and changes in 
me3K27H3 and DNA methylations, as well as the positive correlation between 
me3K27H3 levels and nucleocytoplamic distribution (50). Additionally, the 
concomitant elevation of nuclear SAHH and GNMT tetramers, their active assemblies 
(32, 49), observed in galactosamine-treated livers may contribute to eliminate the 
resulting AdoHcy and to a fine-tuning of AdoMet levels.  
Oxidative stress is among the mechanisms inducing nuclear localization of 
proteins (21, 41), but it is also involved in the control of epigenetic modifications (13). 
Galactosamine, APAP and BSO are known to produce oxidative stress, resulting in 
reduced GSH/GSSG ratios, and all induce nuclear accumulation of MATα1. NAC and 
EGSH, precursors for GSH synthesis (29), normalize this ratio preventing changes in 
MATα1 localization induced by the treatments. In contrast, AdoMet, as previously 
shown (28), is unable to normalize the GSH/GSSG ratio, and hence does not prevent 
MATα1 nuclear accumulation. These results suggest the implication of a glutathione-
dependent mechanism in nuclear localization of MATα1 that for APAP may involve 
additional processes. Accordingly, NAC does not prevent APAP effects on DNA or 
me3K27H3 methylations in H35 cells, but increases global DNA methylation in 
galactosamine-treated cells and prevents the rise in me3K27H3. This positive 
correlation between nuclear MATα1 levels and me3K27H3, a known repression mark 
(6), is observed with both drugs, suggesting the need to down-regulate certain genes that 
may have been activated by the global DNA hypomethylation normally associated with 
increased MAT2A expression (8, 15, 24), and for which our rat models show a trend. 
Altogether the available results suggest the preference of MAT I to supply AdoMet for 
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me3K27H3 methylation, whereas MAT II subunits were found interacting with several 
methyltransferases involved in me2K4H3 and me2K9H3 (26). These epigenetic 
modifications have been studied specially in cancer and have been associated with 
either repression (me3K27H3 and me2K9H3) or activation (me2K4H3) of gene 
expression (55, 51), the final outcomes depending on the genes affected. Overall, 
changes induced by the treatments on hepatic MATα1 make hepatocytes approach the 
extrahepatic cell pattern, where this protein is poorly expressed and preferentially 
localized to the nucleus (50).  
 In summary, our data indicate that AdoMet homeostasis in liver injury is 
sustained by changes involving from transcription to activity and subcellular 
localization of methionine metabolism enzymes. The GSH/GSSG ratio controls 
MATα1 subcellular distribution, its decrease leading to MAT I nuclear accumulation to 
supply the increased AdoMet needs for epigenetic remodeling. Concomitantly, SAHH 
nuclear accumulation contributes to preclude methyltransferase inhibition, maintaining 
the methylation index. Altogether these findings unveil new implications for the 
regulation of these enzymes in disease.  
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INNOVATION 
 The relationship between changes in subcellular localization of methionine 
metabolism enzymes and disease was analyzed in acute liver injury. The results 
demonstrate that S-adenosylmethionine homeostasis is compromised due to a variety of 
processes, including from changes in expression to altered subcellular distribution of 
key proteins controlling the S-adenosylmethionine/S-adenosylhomocysteine ratio. 
Remodeling of methylation-based epigenetic modifications is fulfilled by nuclear 
accumulation of methionine adenosyltransferase I and S-adenosylhomocysteine 
hydrolase. Glutathione levels regulate subcellular distribution of these enzymes, effects 
that are prevented by N-acetylcysteine. These alterations in nucleocytoplasmic 
localization show a potential as markers of disease. 
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MATERIALS AND METHODS 
 Animal models. Male Wistar rats (180-200 g) were divided into four groups (25 
animals each) that received i.p. injections at 24 hour intervals of: PBS (control 1 and 2 
groups), D-galactosamine hydrochloride (400 mg/kg; Sigma, St. Louis MO) or APAP 
(250 mg/kg; Sigma). Animals were sacrificed after 24 (control 1 and APAP groups) or 
48 hours (control 2 and galactosamine groups) and blood, liver and kidneys extracted. 
Tissues were processed immediately for subcellular fractionation or frozen in liquid 
nitrogen for storage at –80ºC. All animals were treated according to the Guidelines for 
Animal Experimentation of the CSIC and the European Union. 
 Histology and immunohistochemistry. Liver samples and one kidney of each 
individual were fixed in formaldehyde 10% (v/v) before being embedded in paraffin. 
Sections (10 microns) were prepared and used for morphological analysis after standard 
hematoxylin/eosine staining.  
Immunohistochemistry was performed on paraffin sections (5 µm) using anti-
MATα1 or preimmune rabbit sera (1:1000, v/v), followed by EnVision (DAKO 
Corporation, Carpinteria CA) as previously described (50). Counterstaining was 
performed with hematoxylin. Sections were photographed and analyzed using Adobe-
Photoshop CS software v. 8.0.1. 
Liver function analysis. Serum samples were obtained by standard protocols 
after incubation at 37ºC for 20-30 minutes. Transaminase levels were analyzed at the 
Centro de Análisis Sanitarios of the Universidad Complutense de Madrid (Facultad de 
Farmacia, Madrid, Spain). 
 Plasmids, expression and characterization of tagged proteins. The pHA(del) 
plasmid was prepared by deletion of C876 of pCMV-HA (Clontech, Mountain View 
CA) to allow in-frame cloning of the rat MAT1A ORF that was obtained by EcoRI/NotI 
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(Invitrogen-Life Technologies, Carlsbad CA) digestion of pSSRL-BlueT2 (1). The 
resulting plasmid was named pHA-MAT. The HA-MATα1 protein contains the 
LMAMEAEFH linker sequence, increasing its size by ∼2 kDa. Protein characterization 
was carried out by MAT activity determinations (160 µl), western blot (80 µg) and 
analytical gel filtration chromatography (100 µl) using the soluble fraction obtained 
after overexpression into BL21(DE3) cells, as previously described (2, 50). The results 
were compared with soluble fractions of cells transformed with pHA(del) 
(Supplementary Fig. S3-S5). Additional plasmids used in this work, pFLAG-MAT and 
pMAT-EGFP, were previously described and both FLAG-MATα1 and MATα1-EGFP 
proteins characterized (50).  
 Cell culture and treatments. Rat hepatoma H35 cells were grown in DMEM 
medium (Gibco-Life Technologies) containing 10% (v/v) FBS and 2 mM glutamine. 
Transient transfections with pFLAG-MAT, pMAT-EGFP or pHA-MAT constructs 
were carried out using Lipofectamine for 6-8 hours (Invitrogen-Life Technologies). 
Concentrations of the agents (Sigma) used in the treatments were as follows: 10 mM D-
galactosamine (Gal); 5 mM NAC; 0.5 mM AdoMet chloride; 1 mM BSO; 1 mM 
EGSH; and 5 mM APAP. All the agents were diluted in PBS, except for APAP that was 
dissolved in ethanol (1% v/v final concentration). BSO and APAP treatments were 
carried out for 24 hours, whereas galactosamine was added for 48 hours. NAC was 
added 12 hours before galactosamine or APAP, whereas AdoMet and EGSH were 
supplied 15 min prior to either galactosamine or BSO administration. 
 For half-life experiments H35 cells (300000 cells) were seeded and grown 
overnight. Three plates per time point were prepared containing either PBS (controls) or 
D-galactosamine (treated) for 48 hours. The culture medium was then replaced with 
serum-free medium and 20 µg/ml cycloheximide (Sigma) or 5 µg/ml actinomycin D 
Delgado et al. 
 22 
(Sigma) added to the plates. Samples were collected at different time points up to 24 
hours to obtain either the cytosolic fractions or total RNA, and the effects on each 
protein or mRNA were analyzed by western blot or real-time RT-PCR, respectively. 
The values were corrected against α-tubulin (western blot) or the 18S transcript, and the 
half-lives calculated using GraphPad Prism v. 5.0. 
 Confocal microscopy. H35 cells were grown on coverslips for indirect 
immunofluorescence (40000 cells) or in vivo (100000 cells) confocal microscopy and 
transient transfections with pFLAG-MAT or pMAT-EGFP carried out before treatment, 
using the conditions described above. Nuclei were stained for 1 hour using Hoechst 
33342 (5 µg/ml; Molecular Probes, Carlsbad CA) before cell fixation or direct 
observation. Fixation was carried out using 2% (v/v) formaldehyde, followed by 
permeabilization using 0.3% (v/v) Triton X-100 (Calbiochem-Merck, Darmstadt, 
Germany) as previously described (50). Fixed cells were incubated for 1 hour 
sequentially with monoclonal mouse M2 anti-FLAG (5 µg/ml; Sigma) and anti-mouse-
Alexa Fluor 488 (Molecular Probes). Glass coverslips were mounted using Prolong 
Gold anti-fade reagent (Invitrogen). Cell imaging (0.3-0.4 µm sections) was performed 
on a Leica TCS SPII Spectral microscope using a 63x/1.3 NA objective at the Confocal 
Microscopy facilities of the Universidad Autónoma de Madrid (UAM). Images were 
analyzed using the Leica Confocal Software (LCS Lite, Zurich, Switzerland).  
 Subcellular fractionation. Rat liver samples were homogenized in 4 volumes 
of 10 mM Tris/HCl pH 7.4 containing 0.3 M sucrose, 0.1 mM EGTA, 0.1% 2-
mercaptoethanol (Merck, Darmstadt, Germany), 1 mM benzamidine (Sigma), 0.1 mM 
PMSF (Sigma) and 10 µg/ml soybean trypsin inhibitor (Sigma). Homogenates were 
centrifuged at 12500 xg for 15 min at 4ºC and the supernatants ultracentrifuged at 
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105000 xg for 1 hour at 4ºC. This second supernatant, the cytosolic fraction, was used 
for activity measurements, AGFC and Western blot.  
 Separation of nuclear and cytoplasmic fractions was carried out in the absence of 
detergents as previously described (3, 50). For this purpose, liver samples (∼8 g) or H35 
cells (2 x106/p100), wild type and transiently transfected with pFLAG-MAT or pHA-
MAT, were used. Samples of subcellular fractions were utilized for western blot, AGFC 
and activity determinations. Cross-contamination among fractions was monitored by 
measuring LDH activity as described previously (50), and by densitometric scanning of 
the immunoblot signals for the marker proteins α-tubulin (cytoplasm) and lamin B1 
(nucleus) and found to be <0.08%. Cell extracts for evaluation of histone methylation 
were obtained by a 30 minute incubation on ice in 50 mM Tris/HCl pH 7.5, 150 mM 
NaCl, 0.5% (v/v) SDS, 30 mM sodium pyrophosphate, 50 mM NaF and protease 
inhibitors, followed by centrifugation at 100000 xg 30 minutes. 
 Quantitative RT-PCR. Total RNA was isolated from livers of control and 
treated animals using the RNeasy kit (Qiagen, Hilden, Germany), and the quality and 
quantity determined spectrometrically and by automated electrophoretogram on a 
Bioanalyzer 2100. Reverse transcription and PCR were done as previously described 
using 1.25 µg of total RNA as template and the High Capacity Archive kit (Applied 
Biosystems-Life Technologies)(14). The cDNAs (10 ng) were amplified in triplicate 
using gene specific primers (Supplementary Table 5) and Power SYBR Green PCR 
Master Mix (Applied Biosystems) using the ABI 7900HT Real-Time PCR system 
(Applied Biosystems) at the Genomic Service of the Instituto de Investigaciones 
Biomédicas “Alberto Sols” (CSIC-UAM). Fluorescent signals were collected after each 
extension step, and the curves analyzed with SDS 2.2.2 software. Relative expression 
ratios were normalized to the geometric mean of the 18S gene used as a control. 
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Experimental efficiencies were calculated for each transcript and used to obtain the fold 
changes according to Pfaffl (47). 
 Activity measurements. Samples of the subcellular fractions were used to 
determine MAT, BHMT and LDH activities as described previously (18, 19, 50). 
Briefly, cytosolic MAT activity measurements were carried out for 30 min using 160 µl 
samples and three types of reaction mixtures that differ mainly in their methionine 
(Sigma) content: i) 5 mM (total activity; standard mixture); ii) 60 µM (MAT I and MAT 
II activities); and iii) 60 µM plus 10% (v/v) DMSO (MAT I, MAT II and stimulated 
MAT III activities). MAT activity measurements in AGFC fractions (100 µl) and 
nuclear extracts (160 µl) were performed using the standard mixture for 30 minutes and 
2 hours, respectively. For BHMT activity determinations, cytosols (75 µl) were used 
and reactions carried out for 30 minutes. LDH activity was followed at 340 nm and 
37ºC for 5 min using subcellular fractions (10-100 µl) or culture media (100 µl) in 50 
mM Tris/HCl pH 7.5, 0.2 mM NADH (Sigma) and 1 mM sodium pyruvate (Sigma).  
 Analytical gel filtration chromatography (AGFC). Subcellular fractions (100 
µl) were loaded on a Superose 12 10/300 GL column (GE Healthcare, Barcelona, 
Spain) equilibrated and eluted at 0.3 ml/min in 50 mM Tris/HCl pH 8, 10 mM MgSO4, 
1 mM EDTA containing 150 mM KCl. Fractions (210 µl) were collected for activity 
measurements and/or dot-blot analyses. Standards (GE Healthcare and Sigma) for 
column calibration and their elution volumes are indicated in the figure legends.
 Western blot and Dot blot. Liver cytosols (25 µg) or H35 cytosolic samples  
(80 µg) and nuclear fractions (150 µg) were loaded on 10% SDS-PAGE gels and 
transferred to nitrocellulose membranes (GE Healthcare) for incubation with antibodies 
against: MATα1 (1:10000 v/v)(31), BHMT (1:20000 v/v)(19), SAHH (1:1000 v/v; 
Santa Cruz sc-55759, Santa Cruz CA), GNMT (1:1000 v/v; Santa Cruz sc-68871), 
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FLAG (2.5 µg/ml; Sigma), HA (1:1000 v/v; Covance, Madrid, Spain), α-tubulin 
(1:2500 v/v; Sigma) or lamin B1 (1:1000 v/v; Abcam, Cambridge, UK). In contrast, 
evaluation of caspase-3 activation (50 µg/lane) and histone methylation (10 µg/lane) 
were performed on 14% SDS-PAGE gels and western blots incubated with anti-
caspase-3 (1:1000 v/v; Cell Signalling, Danvers MA) or anti-me3K27H3 (1 µg/ml; 
Upstate-Millipore, Charlottesville VA), respectively. Western blot signals were 
developed using the Western Lightning Chemiluminescence Reagent (Perkin Elmer 
Life Sciences, Waltham MA) and densitometric scanning was carried out using ImageJ 
v. 1.37 (http://rsb.info.nih.gov/ij/). Values were normalized against the α-tubulin or 
lamin B1 controls for comparison.  
 For Dot blot analysis aliquots (100 µl) of the column fractions were spotted onto 
nitrocellulose membranes as previously described (54), and incubated with the 
antibodies of interest using the same dilutions as for western blot.  
 Analysis of metabolite levels. Quantification of metabolite levels was 
performed, as previously described, at OWL Genomics facilities (Derio, Vizcaya, 
Spain)(14). Briefly, tissue samples were homogenized in 0.4 M perchloric acid and the 
supernatant used to determine reduced (GSH) and oxidized (GSSG) glutathione levels. 
AdoMet, AdoHcy, Hcy and methionine were measured after 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate derivatization using the AccQ Tag Ultra derivatization 
kit (Waters, Milford MA). Samples were analyzed at 50ºC using a BEH C18 column 
(Waters) and a gradient from 0.05% formic acid: water (buffer A) to 0.05% formic acid: 
acetonitrile (buffer B) coupled to ESI detection (UPLC-MS). Glutathione levels in H35-
treated cells were determined by the method of Tietze. 
 Global DNA methylation. Genomic DNA from liver samples or H35 cells was 
extracted using the DNeasy kit (Qiagen). The quality and quantity of the purified DNA 
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was determined spectrophotometrically (A260/A280 ratio). Samples (200 ng/well) were 
used to determine global DNA methylation levels using the IMPRINT® Methylation 
DNA Quantification kit (Sigma) following manufacturer’s instructions. 
 Protein concentration determinations. Protein concentration was measured 
using the BioRad protein assay and bovine serum albumin as the standard. 
 Statistics. GraphPad Prism v. 5.0 (GraphPad Software) was used for statistical 
analysis of the data. Experiments containing two groups of data were analyzed using 
Student’s t-test for independent samples, whereas one-way ANOVA with Bonferroni 
post-hoc test was preferred for multiple comparisons; differences were considered 
significant when p≤ 0.05. 
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LIST OF ABBREVIATIONS 
AdoHcy, S-adenosylhomocysteine  
AdoMet, S-adenosylmethionine  
AGFC, analytical gel filtration chromatography 
APAP, acetaminophen 
BHMT, betaine homocysteine methyltransferase  
BSO, buthionine sulfoximine 
EGFP, enhanced green fluorescence protein 
EGSH, glutathione ethyl ester 
Gal, D-galactosamine 
GCL, γ-glutamylcysteine synthetase 
GNMT, glycine N-methyltransferase  
GSH, glutathione reduced form 
GSSG, glutathione oxidized form 
HCC, hepatocellular carcinoma 
Hcy, homocysteine 
HuR, human antigen R 
MafK, Maf oncoprotein K 
MAT, methionine adenosyltransferase 
me2K4H3, histone 3 K4 dimethylation  
me2K9H3, histone 3 K9 dimethylation  
me3K27H3, histone 3 K27 trimethylation  
MTHFR, methylene tetrahydrofolate reductase 
MTR, methionine synthase  
NAC, N-acetylcysteine 
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NAPQI, N-acetyl-p-benzoquinone imine 
N/C, nuclear to cytoplasmic signal ratio 
NO, nitric oxide 
UPLC-MS, ultraperformance liquid chromatography- mass spectrometry 
ROS, reactive oxygen species 
SAHH, S-adenosylhomocysteine hydrolase  
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FIGURE LEGENDS 
 FIG. 1. Analysis of expression changes by real-time RT-PCR. Changes in 
steady-state mRNA levels of enzymes of the hepatic methionine cycle and glutathione 
synthesis induced by D-galactosamine were analyzed by real-time RT-PCR. (A) Fold 
change in the galactosamine-treated group (N=16) calculated against the control group 
(N=16) using the 18S gene as reference (mean ± SD). Statistical evaluation was 
performed using ratios for each transcript vs. 18S (*p<0.05). (B) MAT transcript 
changes (mean ± SD) within control (left) and galactosamine (right) groups using 
control MTR levels as reference for graphical purposes. Multiple comparisons were 
performed and changes considered significant when p<0.05 (*vs. control MAT1A; ** 
vs. control MAT2A; *** vs. control MAT2B). 
 FIG. 2. Western blot analysis of cytosolic methionine cycle enzymes. 
Samples of liver cytosols (25 µg) from control (N=16) and galactosamine-treated 
(N=16) rats were used for immunoblotting. (A) Representative blots of animals in each 
group. (B) Quantification of the signals for each protein corrected against α-tubulin 
(mean ± SD) of animals in the control (black bars) and galactosamine groups (white 
bars). (C-E) Results from wild type and (F) pHA-MAT transiently transfected H35 cells 
treated with PBS (control) or galactosamine (gal). Cytoplasmic samples (20-30 µg/lane) 
were used for immunoblotting using anti-BHMT (C), anti-SAHH (D), anti-GNMT (E) 
or anti-HA (F) and anti-α-tubulin (loading control). Student’s t-tests of the data were 
performed against the corresponding control group (*p≤ 0.05). 
 FIG. 3. In vivo and indirect fluorescence confocal microscopy of transiently 
transfected H35 cells after D-galactosamine treatment. Hepatoma H35 cells were 
transiently transfected with pFLAG, pFLAG-MAT, pEGFP or pMAT-EGFP. The plates 
were divided into two groups that were treated for 48 hours with PBS (control) or 10 
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mM galactosamine. Representative examples of the expression of tagged-MATα1 in 
control and treated cells visualized by confocal microscopy are shown. (A) Indirect 
immunofluorescence of FLAG-MATα1 localization using anti-FLAG. (B) In vivo 
results with MATα1-EGFP. Colocalization with nuclear staining is shown in white (bar 
scale, 25 µm). Histograms show quantification of the nucleo/cytoplasmic ratio (mean ± 
SD) obtained with FLAG (C) and EGFP (D) transfected cells of five independent 
experiments carried out in triplicate (*p≤ 0.05). C=N when N/C=1 ± 0.2. To see this 
illustration in color the reader is referred to the web version of this article at 
www.liebertonline.com/ars 
 FIG. 4. Western blot analysis of nuclear fractions. Nuclear fractions (100 
µg/lane) of pHA-MAT and wild type transfected H35 cells were analyzed by western 
blot using anti-HA (A) or anti-SAHH (B), anti-tubulin and anti-lamin B1 as 
cytoplasmic and nuclear markers, respectively. Signals were quantified and corrected 
against lamin B1 for comparison (mean ± SD). Representative blots of five independent 
experiments carried out in triplicate are shown. (C) Representative immunoblots of liver 
nuclear fractions from control (N=6) and galactosamine (N=6) treated rats incubated 
with the antibodies indicated on the left. (D) Quantification of the blots (mean ± SD). 
Statistical analysis was performed by Student’s t-test (* p≤ 0.05). 
 FIG. 5. Subcellular distribution of MATα1 in liver samples analyzed by 
immunohistochemistry. Paraffin sections (5 µm thick) of liver samples from control 
and D-galactosamine-treated rats were incubated with anti-MATα1 or preimmune sera 
and counterstained with hematoxylin. Preimmune serum gave no signal in control (A), 
and galactosamine-treated livers (B,C). In contrast, anti-MATα1 signal was detected in 
hepatocyte cytosols of control (D) and galactosamine livers (E,F), whereas a mixture of 
positive (arrows) and negative (arrowheads) nuclear staining was visible in the treated 
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samples. Panels C and F show a lower magnification view of the liver sections. Scale 
bars correspond to 10 µm (A,B,D,E) and 25 µm (C,F). To see this illustration in color 
the reader is referred to the web version of this article at www.liebertonline.com/ars 
 FIG. 6. Analysis of the association state of nuclear methionine metabolism 
enzymes. Livers of control (C; N=10) and galactosamine-treated rats (Gal; N=8) were 
used for subcellular fractionation. Representative AGFC profiles of nuclear fractions of 
control and treated animals obtained by dot-blot analysis are shown: (A) anti-GNMT, 
(B) anti-SAHH, (C) anti-MATα1. Elution positions for tetramers (T) and monomers 
(M) are indicated. (D) MAT monomer/tetramer ratio (mean ± SD) calculated from the 
dot-blot data of six independent experiments carried out in duplicate. Data were 
analyzed by Students t-tests (*p≤ 0.05). Protein standards used for column calibration 
and their elution volumes were as follows: blue dextran (2000 kDa; 7.13 ml), apoferritin 
(443 kDa; 9.55 ml), β-amylase (200 kDa; 10.38 ml), alcohol dehydrogenase (150 kDa; 
11.05 ml), conalbumin (75 kDa; 11.88 ml), ovalbumin (43 kDa; 12.5 ml), carbonic 
anhydrase (29 kDa; 13 ml) and ATP (551 Da; 17.39 ml). 
 FIG. 7. Effect of redox-modulating agents on H35 cells. Cytosolic and nuclear 
fractions of hepatoma H35 cells transiently transfected with pHA-MAT, and incubated 
with the agents indicated in the figure, were analyzed by western blot. Representative 
western blots of eleven independent experiments are shown together with quantification 
of the data; (A,B) cytosolic HA-MATα1/tubulin and (C,D) nuclear HA-MATα1/lamin 
B1 ratios. Histograms present the results (mean ± SD) as percentage of the control 
(PBS). Multiple comparisons were performed with ANOVA vs. control (*p≤0.05) and 
BSO or D-galactosamine (Gal; **p≤0.05). 
 FIG. 8. Effects of redox-modulating agents on nuclear methylations. (A) 
Global DNA methylation levels (mean ± SD) from control (N=6) and galactosamine-
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treated livers (N=6). (B, C) Hepatoma H35 cells transiently transfected with pHA or 
pHA-MAT and treated with the indicated agents were used to obtain genomic DNA or 
cell extracts. (B) Global DNA methylation levels (mean ± SD) from treated cells were 
calculated from data of three independent experiment carried out in triplicate using a 
standard curve of methylated control DNA. Multiple comparisons were performed with 
ANOVA (*p≤0.05 vs. pHA; ** vs. PBS; *** vs. Gal). (C) Representative immunoblots 
of me3K27H3 levels from four independent experiments carried out in triplicate are 
shown. The mobility and size of the standards is indicated on the right. (D) 
Quantification of me3K27H3 signals corrected against HA-MATα1 levels (mean ± 
SD); tubulin signals were used as loading controls. Multiple comparison were 
performed with ANOVA and differences were considered significant when p≤0.05 (* 
vs. PBS; ** vs. Gal). 
 
ex
pr
es
si
on
 le
ve
ls
600
400
800
200
20
10
MA
T1
A
MA
T2
A
MA
T2
B
MA
T1
A
MA
T2
A
MA
T2
B
control                  galactosamine
30
1000
1200
A
B
fo
ld
 c
ha
ng
e
8
4
 2
6
10
18
S
MA
T1
A
MA
T2
A
MA
T2
B
GN
MT
SA
HH MT
R
BH
MT
GC
Ll
GC
Lm
**
***** ***
***
A                          B
C       Gal  
α-tubulin
MATα1
BHMT
SAHH
GNMT
E                                 F
 p
ro
te
in
/tu
bu
lin
 r
at
io
MATα1 BHMT SAHH GNMT
1.5
1
2
0.5
C                                 D
BH
M
T/
tu
bu
lin
 ra
tio 1.2
BHMT
Tubulin
C           gal
C           gal
0.8
0.4
*
C         gal
SAHH
Tubulin
SA
H
H
/t
ub
ul
in
 ra
tio
0.6
0.4
0.2
C             gal
0.8 *
GNMT
Tubulin
C         gal
G
N
M
T/
tu
bu
lin
 ra
tio
  C            gal
0.6
0.4
0.2
0.8
HA-MATα1
Tubulin
C          gal
  H
A
/t
ub
ul
in
 ra
tio
C            gal
1.5
1.0
0.5
2.0
*
AB
FLAG-MATα1
  FLAG-MATα1
               +
galactosamine
FLAG
MergeFLAGHoechst
EGFP
  MATα1-EGFP
              +
galactosamine
        EGFP  +
galactosamine
MATα1-EGFP
EGFPHoechst Merge
C
D
control                         galactosamine
Ce
ll 
ty
pe
 (%
)
C>
N
C=
N
C<
N
C>
N
C=
N
C<
N
100
80
60
40
20
120
EGFP                           MATα1-EGFP
control            gal                 control             gal
Ce
ll 
ty
pe
 (%
)
100
80
60
40
20
C>
N
C=
N
C<
N
C<
N
C<
N
C>
N
C>
N
C=
N
C=
N
C>
N
C=
N
C<
N
A                                    B
HA-MATα1
lamin B
Tubulin
C          gal
H
A
-M
AT
α1
/la
m
in
 B
 ra
tio
2.5
2.0
1.5
1.0
0.5
C           gal
*
C             gal
SAHH
lamin B
Tubulin
SA
H
H
/la
m
in
 B
 ra
tio
2.0
1.5
1.0
0.5
  C            gal
*
C
C        Gal
anti-GNMT
anti-SAHH
anti-tubulin
anti-lamin B
anti-MATα1
D
G
N
M
T/
la
m
in
B 
ra
ti
o
C                       Gal
4
3
2
1
5
S
A
H
H
/la
m
in
 B
 ra
tio
C                        Gal
*
3
2
1
4
M
AT
α1
/ l
am
in
 B
 ra
tio 5
4
3
2
1
C                     Gal
*
preMAT
control 40x
GLSM 40x
GLSM 20x
A1, B1, C1
MAT
control 40x
GLSM 40x
GLSM 20x
A2, B2, C2
A                                   B                                  C
D                                  E                                  F
preimmune
anti-MATα1
control                                D-galactosamine                      D-galactosamine
A                                             B
G
N
M
T 
d
en
si
to
m
et
ry
 (A
.U
.)
100000
80000
60000
40000
20000
 8            10           12            14           16
elution volume (ml)
control
100000
80000
60000
40000
20000
G
N
M
T 
d
en
si
to
m
et
ry
 (A
.U
.)
 8            10           12            14           16
elution volume (ml)
galactosamine
60000
20000
40000
SA
H
H
 d
en
si
to
m
et
ry
 (A
.U
.)
 8            10           12            14           16
elution volume (ml)
control
60000
20000
40000
SA
H
H
 d
en
si
to
m
et
ry
 (A
.U
.)
 8            10           12            14           16
elution volume (ml)
galactosamineT
T
T
T
C
30000
20000
10000
M
AT
α1
 d
en
si
to
m
et
ry
 (A
.U
.)
 8            10           12            14           16
elution volume (ml)
T
galactosamine
elution volume (ml)
30000
20000
10000
 8            10           12            14           16
M
AT
α1
 d
en
si
to
m
et
ry
 (A
.U
.)
T
Mcontrol
M
D
   
M
on
om
er
/t
et
ra
m
er
   
   
   
 M
AT
α1
 ra
tio
 C                      Gal
10
8
6
4
2
12
A                                                            B
C                                                              D
H3
5
PB
S
NA
C
Ga
l +
 Ad
oM
et
Ad
oM
et
Ga
l +
 N
ACGa
l
HA-MATα1
Tubulin
%
 o
f c
on
tr
ol
 
150
100
50
    
  P
BS
Ad
oM
et
Ga
l +
 Ad
oM
et
Ga
l +
 N
ACNA
C Ga
l
HA-MATα1
Tubulin
H3
5
PB
S
BS
O
BS
O 
+ 
Ad
oM
et
Ad
oM
et
BS
O 
+ 
EG
SH
EG
SH
%
 o
f c
on
tr
ol
 
    
  P
BS BS
O
BS
O 
+ A
do
Me
t
BS
O 
+ E
GS
H
Ad
oM
et
EG
SH
200
150
100
50
H3
5
PB
S
NA
C Ga
l
Ga
l +
 N
AC
Ga
l +
 Ad
oM
et
Ad
oM
et
Tubulin
HA-MATα1
lamin B1
%
 o
f c
on
tr
ol
 
300
200
100
    
   P
BS
Ad
oM
et
Ga
l +
 Ad
oM
et
Ga
l +
 N
ACNA
C Ga
l
H3
5
PB
S
BS
O
BS
O 
+ A
do
Me
t
Ad
oM
et
BS
O 
+ E
GS
H
EG
SH
HA-MATα1
lamin B1
Tubulin
%
 o
f c
on
tr
ol
 
    
   P
BS BS
O
BS
O 
+ A
do
Me
t
BS
O 
+ E
GS
H
Ad
oM
et
EG
SH
200
150
100
50
250
kDa
anti-HA - 48
- 63
anti-me3K27H3
- 10
- 17
anti-Tubulin - 48
- 63
HA PB
S
Ga
l
NA
C
NA
C +
 G
al
HA-MATα1
A                         B
C
D
m
e3
K2
7H
3/
H
A
-M
AT
α1
 ra
tio
HA PB
S Ga
l
NA
C
NA
C +
 G
al
3
2
1
4
HA-MATα1
m
et
hy
la
te
d 
D
N
A
 (n
g)
C            Gal
200
150
100
50
m
et
hy
la
te
d 
D
N
A
 (n
g)
HA PB
S
Ga
l
NA
C
NA
C +
 G
al
HA-MATα1
250
200
100
150
50
Delgado et al. 
 
 1 
Supplementary information 
 
 
ACUTE LIVER INJURY INDUCES NUCLEOCYTOPLASMIC 
REDISTRIBUTION OF HEPATIC METHIONINE METABOLISM ENZYMES 
 
Miguel Delgado, Francisco Garrido, Juliana Pérez-Miguelsanz, María Pacheco, Teresa 
Partearroyo, Dolores Pérez-Sala and María A. Pajares 
 
 
INDEX OF CONTENTS 
 
Supplementary FIG. S1 ................................page 2 
Supplementary Table S1 ..............................page 3 
Supplementary Table S2 ..............................page 4 
Supplementary FIG. S2  ...............................page 5 
Supplementary FIG. S3 ................................page 6 
Supplementary FIG. S4 ................................page 6 
Supplementary FIG. S5 ................................page 7 
Supplementary Table S3 ..............................page 8 
Supplementary FIG. S6  ..............................page 9 
Supplementary FIG. S7 ...............................page 10 
Supplementary FIG. S8 ...............................page 11 
Supplementary FIG. S9 ...............................page 12 
Supplementary FIG. S10 .............................page 13 
Supplementary Table S4 ..............................page 14 
Supplementary FIG. S11 .............................page 15 
Supplementary FIG. S12 .............................page 16 
Supplementary FIG. S13 .............................page 17 
Supplementary FIG. S14 .............................page 18 
Supplementary FIG. S15 .............................page 19 
Supplementary Table S5 ..............................page 20 
 
 
Delgado et al. 
 
 2 
 
 
Supplementary FIG. S1. Histological evaluation of the livers of control and D-
galactosamine-treated rats. Paraffin embedded sections of livers from control (A, 
D,G) and galactosamine–treated animals (B, C, E, F, H, I) were prepared for 
hematoxylin-eosin staining. The figure shows representative panels for individuals in 
each group, proving the presence of acute liver injury in the treated animals. Focal 
necrosis (∗), Kupffer cell hyperplasia and inflammatory cell infiltration (arrowheads) 
were visible. In one case, fat infiltration (+) in the periportal area was also observed (B, 
E, H). Locations of portal vessels (p) and central vein (v) are also indicated. The bar 
scale corresponds to 50 µm (A-C), 20 µm (D-F) and 10 µm (G-I). 
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Supplementary Table S1 
 Activity measurements. Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) activities were measured in serum, whereas MAT and BHMT 
activities were determined in liver cytosol from control and D-galactosamine-treated 
animals receiving two 400 mg/kg i.p. doses of the agent as described under Materials 
and Methods. The assay conditions correspond to: total MAT activity (5 mM 
methionine); MAT I and MAT II activities (60 µM methionine); and MAT I, MAT II 
and stimulated MAT III activities (60 µM methionine plus 10% v/v DMSO). Activity in 
MATα1 tetramer (MAT I) and dimer (MAT III) peaks obtained by AGFC was 
measured at saturating concentrations of the substrates to calculate the MAT I/III 
activity ratio for animals in each group. The data shown are the mean ± SD of 
measurements made in triplicate for every individual in each group.  
 
 Assay conditions control 
(n=15) 
galactosamine 
(n=16) 
p 
value 
ALT (U/l) serum 28.33 ± 3.41  1212 ± 454.2* <0.001 
AST (U/l) serum 131.5 ± 22.32 2466.0 ± 749.8* <0.001 
60 µM Met 50.33 ± 3.43 54.03 ± 3.17 0.51 
60 µM Met + 10% DMSO 503.34 ± 34.27 622.31 ± 51.49 0.17 
 
MAT 
(pmol/min/mg) 
5 mM Met 689.0 ± 132.2 336.1 ± 43.57* 0.04 
 
BHMT 
(nmol/min/mg) 
 
6.5 mM Betaine + 6.5 mM 
Hcy 
 
0.268 ± 0.05 
 
0.197 ± 0.07* 
 
0.02 
MAT III/I 
ratio 
5 mM Met 1.08 ± 0.11 1.45 ± 0.56 0.29† 
*significant, p≤ 0.05. 
†variances significantly different according to Bartlett’s test 
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Supplementary Table S2 
 Hepatic metabolite levels determined by UPLC-MS in liver samples of the 
galactosamine model.  
 Control† 
(n=12) 
Galactosamine† 
(n=10) 
p value 
AdoMet (nmol/g) 71.38 ± 14.32 47.98 ± 9.21* 0.03 
AdoHcy (nmol/g) 51.54 ± 10.84 44.88 ± 9.34 0.37 
AdoMet/AdoHcy 1.50 ± 0.19 1.07 ± 0.17* 0.03 
Hcy (nmol/g) 5.34 ± 0.51 6.72 ± 0.97* 0.01 
Methionine (nmol/g) 180.4 ± 42.64 265.3 ± 62.24* 0.03 
GSH (nmol/mg protein) 85.67 ± 26.5 122.0 ± 29.88 0.09 
GSSG (nmol/mg protein) 2.07 ± 0.81 3.99 ± 1.67* 0.04 
GSH/GSSG 43.60 ± 6.13  29.88 ± 10.68* 0.03 
 *significant, p≤ 0.05. 
 † The results are the amount quantified per gram of tissue for each group (mean 
± SD). 
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Supplementary FIG. S2. Gel filtration chromatography profiles of cytosolic MAT 
I/III. Cytosolic samples (1 mg) of control (A and B) and D-galactosamine-treated rat 
livers (C and D) were loaded on a Superose 12/10 HR column and the eluting fractions 
collected. Samples of these fractions were used to measure total MAT activity at 5 mM 
methionine (A and C), and for dot-blot analysis of MATα1 protein (B and D). The 
figure shows profiles of representative samples of each group. The markers eluted as 
follows: blue dextran (7.66 ml), apoferritin (9.87 ml), β-amylase (11.97 ml), alcohol 
dehydrogenase (12.81 ml), carbonic anhydrase (15.12 ml) and ATP (19.26 ml). The 
elution volumes for tetramers (T) and dimers (D) are indicated. 
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Supplementary FIG. S3. HA-MATα1 activity as a function of time. HA-MATα1 
was overexpressed in E. coli BL21(DE3) cells and the soluble fraction isolated. MAT 
activity was measured using a reaction mixture containing 5 mM methionine and 5 mM 
ATP. The reaction was carried out in triplicate at 37ºC and the production of AdoMet 
analyzed at 15, 30, 45 and 60 min. The same analysis was carried out in parallel using 
pHA transformed cells, in order to determine the background provided by the E. coli 
MAT isoenzyme. The figure shows results (mean ± SD) of a representative experiment 
carried out in triplicate. Calculated specific activities were determined for pHA (928.2 ± 
79.15 pmol/min/mg) and pHA-MAT (1995.0 ± 220.7 pmol/min/mg) transformed cells. 
 
 
 
 
          1              2             3 
 
 
Supplementary FIG. S4. HA-MATα1 levels in the soluble fraction of BL21(DE3) 
cells. The figure shows a representative western blot of samples from the soluble 
fraction (lane 1), a 1:10 (v/v) dilution of this fraction (lane 2) and a concentrated sample 
of the HA-MATα1 peak eluted from analytical gel filtration chromatography (lane 3) 
using anti-HA. HA-MATα1 exhibits a calculated molecular mass of 53.8 kDa 
according to the mobility of the standards. The low expression observed in the soluble 
fraction can explain the low level of activity detected. 
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Supplementary FIG. S5. Analytical gel filtration chromatography elution profile of 
HA-MATα1. A sample of the soluble fraction (100 µl) obtained from E. coli 
BL21(DE3) transfected with pHA-MAT was injected onto a Superose 12 10/300 GL gel 
filtration chromatography column and run at 0.3 ml/min. Fractions (210 µl) were 
collected and aliquots (100 µl) were used for Dot-Blot detection of HA-MATα1 using 
anti-HA. The intensity of the spots was established by densitometric scanning using 
ImageJ software and represented against the elution volume. The figure shows a 
representative elution profile of three experiments carried out in triplicate. The elution 
volume of the markers was as follows: blue dextran (7.13 ml), apoferritin (9.55 ml), β-
amylase (10.38 ml), alcohol dehydrogenase (11.05 ml), carbonic anhydrase (13 ml) and 
ATP (17.39 ml). The elution volume of the main peak detected corresponds to that 
expected for a protein of ∼85 kDa, in agreement with that estimated for a dimer of HA-
MATα1 subunits. 
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Supplementary Table S3 
 Effect of D-galactosamine treatment on mRNA and protein half-lives in 
H35 cells. H35 hepatoma cells were treated with 10 mM D-galactosamine for 48 hours 
before addition of 5 µg/ml actinomycin D (†) or 20 µg/ml cycloheximide (¶) in the 
absence of serum to determine mRNA or protein half-lives, respectively. The results 
shown are the average of three experiments carried out in triplicate (mean ± SD) and 
were considered significant when p≤ 0.05 (*). 
 
 mRNA half-life (hours)† 
 Control§ Galactosamine§ p value 
MAT2A 5.83 ± 2.44 6.25 ± 1.78 0.79 
MAT2B 6.76 ± 1.90 12.53 ± 2.44* 0.02 
SAHH 67.36 ± 29.88 9.77 ± 0.70* 0.02 
MTR 12.48 ± 4.16 13.49 ± 10.22 0.86 
BHMT 82.53 ± 77.0 9.58 ± 10.14 0.24 
GCLl 4.00 ± 0.56 7.70 ± 2.06* 0.02 
GCLm 11.23 ± 4.82 39.80 ± 1.88* 0.003 
 Protein half-life (hours)¶ 
BHMT 16.34 ± 6.25 44.20 ± 20.47* 0.05 
SAHH 14.62 ± 3.22 34.85 ± 15.27* 0.01 
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Supplementary FIG. S6. Analytical gel filtration chromatography profiles of 
cytosolic BHMT, GNMT and SAHH. Liver cytosols (100 µl) from control () and 
galactosamine-treated () animals were injected onto a Superose 12 10/300 GL gel 
filtration chromatography column and run at 0.3 ml/min. Fractions (210 µl) were 
collected and aliquots (50 µl) were used for Dot-Blot detection of BHMT (panel A), 
GNMT (panel B) or SAHH (panel C) using the corresponding antibodies. The intensity 
of the spots was established by densitometric scanning using ImageJ software and 
represented against the elution volume. The figure shows a representative elution profile 
of six independent experiments carried out in duplicate. The elution volume of the 
markers was as follows: blue dextran (7.13 ml), apoferritin (9.55 ml), β-amylase (10.38 
ml), alcohol dehydrogenase (11.05 ml), carbonic anhydrase (13 ml) and ATP (17.39 
ml).  
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Supplementary FIG. S7. Glutathione levels in transfected H35 cells subjected to 
different treatments. GSH and GSSG levels were determined in transfected H35 cells 
after the addition of 1 mM BSO (panel A), 10 mM galactosamine (Gal; panel B) or 5 
mM acetaminophen (APAP; panel C) alone or in combination with 5 mM N-
acetylcysteine (NAC), 1 mM glutathione ethyl ester (EGSH) or 0.5 mM AdoMet. 
Appropriate controls including the vehicle (PBS or 1% ethanol) were included for 
comparison. Left panels show calculated GSSG levels, central panels depict the GSH 
content and right panels represent the calculated GSH/GSSG ratio. The results shown 
are the mean ± SD of four independent experiments carried out in triplicate. 
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Supplementary FIG. S8. Effects of buthionine sulfoximine and D-galactosamine 
treatments on caspase-3 activation in pHA-MAT transfected cells. Hepatoma H35 
cells transiently transfected with pHA-MAT were treated with buthionine sulfoximine 
(BSO) for 24 h alone or in combination with AdoMet or EGSH (panel A). Transfected 
cells were also treated for 48 h with galactosamine (Gal) alone or in combination with 
AdoMet or NAC (panel B). Cellular extracts were obtained and samples (50 µg) were 
analyzed by western blot using anti-caspase-3 and anti-tubulin antibodies. 
Representative western blots of nine independent experiments are shown in the figure. 
The mobility and size of the standards is indicated on the right.  
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Supplementary FIG. S9. LDH activity measured in the culture media of H35 cells 
transfected with pHA-MAT. H35 transfected cells were treated with 10 mM 
galactosamine (Gal; 48 hours), 5 mM acetaminophen (APAP; 24 hours), 5 mM N-
acetylcysteine (NAC) or their combinations. LDH activity was measured in the cell 
media (100 µl). The figure shows results (mean ± SD) of six independent experiments 
carried out in triplicate for galactosamine (panel A) and acetaminophen treatments 
(panel B). Multiple comparisons of the data were carried out with ANOVA using 
GraphPad Prism and considered significant when p≤ 0.05 vs. PBS (*), Gal or APAP 
(**). 
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Supplementary FIG. S10. Effects of redox-modulating agents on nucleocytoplamic 
distribution of MATα1-EGFP analyzed by in vivo confocal microscopy. Hepatoma 
H35 cells were transiently transfected with pMAT-EGFP and the effect of several 
additives analyzed in vivo by confocal microscopy. Panels A and D show representative 
confocal images of several treatments, including colocalization with nuclear staining 
(bar scale=10 µm). Nuclear (N) and cytoplasmic (C) EGFP signals were quantified 
using the Leica Confocal Software and the N/C ratio calculated for a minimum of 100 
cells per treatment. Panel B depicts quantification results obtained in experiments with 
BSO (24h); panel C shows data of D-galactosamine (48h) treatments; and panel E 
illustrates quantifications obtained in experiments including acetaminophen (24h). For 
graphical purposes panels B, C and E depict the mean ± SEM of the data analyzed using 
ANOVA with Bonferroni post-hoc testing. Significant changes (p ≤ 0.05) vs. control 
with PBS or ethanol (*), and BSO, galactosamine or acetaminophen (**) are indicated.  
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Supplementary Table S4 
 Activities and metabolite levels in rats treated with acetaminophen. Alanine 
aminotransferase (ALT) and aspartate aminotransferase activities were measured in 
serum samples of control and acetaminophen treated animals. On the other hand, 
metabolite levels and cytosolic MAT activity were determined in liver samples as 
described under Materials and Methods. The activity data shown are the mean ± SD of 
measurements made in triplicate for every individual in each group.  
 
 Assay conditions control 
(n=6) 
acetaminophen 
(n=6) 
p value 
ALT (U/l) Serum 28.33 ± 3.41 1324 ± 453* <0.0001 
AST (U/l) serum 131.5 ± 22.32 2630 ± 1075.8* <0.0001 
AdoMet (nmol/g) liver 77.43± 8.20 59.43 ± 5.05* 0.049 
AdoHcy (nmol/g) liver 48.79 ± 5.33 30.82 ± 3.49* 0.045 
AdoMet/AdoHcy liver 1.42 ± 0.08 2.33 ± 0.27* 0.001 
Hcy (nmol/g) † liver <1.5 <1.5 - 
Methionine (nmol/g) liver 186.6 ± 38.90 94.88 ± 18.54* 0.012 
GSH (nmol/mg 
protein) 
liver 77.31 ± 20.48 41.45 ± 10.37* 0.04 
GSSG (nmol/mg 
protein) 
liver 1.58 ± 0.04 1.15 ± 0.05* 0.001 
GSH/GSSG liver 47.87 ± 3.06  36.34 ± 6.28* 0.049 
60 µM Met 161.5 ± 4.39  128.0 ± 4.91*  0.001 
60 µM Met + 10% 
DMSO 
654.8 ± 25.21 611.4 ± 14.93 0.195 
 
 
MAT 
(pmol/min/mg) 
5 mM Met 2389.0 ± 131.1  1957.0 ± 121.7*  0.027 
MAT III/I activity 
ratio 
5 mM Met 1.08 ± 0.11  2.35 ± 0.70* 0.016 
*significant, p≤ 0.05. 
†below the quantification limit 
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Supplementary FIG. S11. Histological evaluation of liver sections of rats treated 
with acetaminophen. Paraffin embedded sections of livers from acetaminophen–
treated animals were prepared for hematoxylin-eosin staining. The figure shows 
representative photomicrographs proving the presence of a large number of necrotic 
hepatocytes (arrows). The presence of sinusoidal congestion with red blood cells 
(arrowheads) was visible as compared to the normal architecture of control liver 
sections (Supplementary Fig. 1, panels A,D,G). The bar scale corresponds to 100 µm 
(A), 50 µm (B) and 10 µm (C). 
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Supplementary FIG. S12. Effects of acetaminophen treatment on MATα1 
subcellular distribution and oligomerization in rat liver. Cytosolic and nuclear 
fractions were isolated from livers of control and acetaminophen-treated rats. Panel A 
shows MATα1 levels in nuclear fractions using lamin B as the reference, whereas panel 
B illustrates MATα1 levels in the cytosol using α-tubulin as the loading control. 
Representative MAT activity and dot-blot profiles (n=6) of cytosolic samples analyzed 
on a Superose 12 10/300 GL gel filtration chromatography column run at 0.3 ml/min 
are depicted in panel C, whereas a representative dot-blot profile of a nuclear sample 
appears in panel E. The elution volume of the markers was as follows: blue dextran 
(7.13 ml), apoferritin (9.55 ml), β-amylase (10.38 ml), alcohol dehydrogenase (11.05 
ml), carbonic anhydrase (13 ml) and ATP (17.39 ml). Quantification of the cytosolic 
dimer/tetramer activity and protein ratios are shown in panel D, whereas the nuclear 
monomer/tetramer ratio appears in panel F. Panel G illustrates nuclear MAT activity in 
control and acetaminophen-treated livers. The results shown are the mean ± SD of six 
independent samples; p≤0.05 (*). 
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Supplementary FIG. S13. Effects of acetaminophen on DNA and histone 
methylations. The figure shows the effects of acetaminophen (APAP) treatment on 
global DNA methylation in DNA samples of control and acetaminophen treated livers 
(panel A). In addition, the effects of APAP alone or in combination with NAC were 
also evaluated in H35 transfected cells. Panel B, depicts the changes in global DNA 
methylation induced by the treatments in pHA-MAT transfected cells, whereas panel C 
illustrates the alterations observed in K27 trimethylation of histone 3. The histograms 
show the mean ± SD of three independent experiments carried out in triplicate. Multiple 
comparisons were carried out with ANOVA; p≤0.05 vs. control (*) or APAP (**) 
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Supplementary FIG. S14. Effects of acetaminophen treatment on caspase-3 
activation in pHA-MAT transfected cells. Hepatoma H35 cells transiently transfected 
with pHA-MAT were treated with acetaminophen (APAP) for 24 h alone or in 
combination with NAC. Cellular extracts were obtained and samples (50 µg) were 
analyzed by western blot using anti-caspase-3 and anti-tubulin antibodies. 
Representative western blots of five independent experiments are shown in the figure. 
The mobility and size of the standards is indicated on the left.  
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Supplementary FIG. S15. Schematic representation of the cytoplasmic changes in 
the methionine cycle and connecting pathways detected in the animal models used. 
(A) Changes in the galactosamine model and (B) alterations detected in the APAP 
model. Metabolites measured in this study appear in boxes colored according to the 
changes observed, decreased (red), increased (green) and non-modified levels (light 
blue). Metabolites that were not determined appear in white boxes. Changes in mRNA 
levels are indicated as superscripts to the protein symbol, those included in panel B 
were reported by Schnackenberg et al. (56). Again, a color code has been used to 
indicate the alterations observed: decrease (red), increase (light blue) and sharp increase 
(dark blue); black characters indicate no change or undetected protein. Colored arrows 
indicate the favored (green), decreased (red) or unchanged (black) reactions under 
according to our results (galactosamine) and/or Schnackenberg et al. (APAP). Nuclear 
changes in protein levels have been excluded for clarity. 
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Supplementary Table S5 
Primer sequences used for Real Time-PCR experiments designed with Primer 
Express 3.0.  
 Forward (5´-3) Reverse (5´-3´) nM* 
MAT 1A GCGAGAGCTACTAGAGGTTGTGAA AGATCCAAGTCCCTGACAATAACAC 300 
MAT 2A GGAGGGTTCTTGTTCAGGTCTCT GGAAAATGGAGATCGACAATGG 300 
MAT 2B GCAATTGCAGACGCCTTCA CAGGGCTGTCAGTAATAGGTCGTA 300 
BHMT GGAGATCTACATGGCGTGTCT CGGCACCTGCTTTTACCAAA 300 
MS TCTGTGAAGACCTCATCTGGAACA  TGAGAATGCTATACGGGT  300 
SAHH GGGCGGTGACCTTACTAACCTCAT  TCGAAGACAGTCCTAGGCT  300 
GCSl TCTGCCCAATTGTTATGGCTTT GTCTGACACGTAGCCTCGGTAA 300 
GCSm GCACAGGTAAAACCCAATAGTAATCAA CAGTCAAATCTGGTGGCATCA 300 
GNMT GGCACAGGAGTGGACTCGAT ATCCACACTCGTGACGCTAAAG 300 
18S CCAGTAAGTGCGGGTCATAAGC CCGATTGGATGGTTTAGTGAGG 100 
*concentrations used in PCR reactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
